Article History
Received: 16 May 2023
Revised: 16 June 2023
Accepted: 20 June 2023
First Online: 30 June 2023
Competing interests
: HdW is supported by PHS DA02812. HdW is a scientific advisor for Gilgamesh Pharmaceuticals and Awakn Life Sciences, and serves on the Board of Directors of PharmAla Biotech. MH is supported by the Swedish Research Council 2013–07434 and the Knut and Alice Wallenberg Foundation. He has in the past 5 years received consulting fees, research support, or other compensation from Indivior, Camurus, Molteni, BrainsWay, Aelis Farma, Lundbeck and Janssen Pharmaceuticals, and he is an Associate Editor of Neuropsychopharmacology. AKB has nothing to disclose.